Novartis: Hepatitis C trials
The registry lists 10 Hepatitis C studies with Novartis as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 1Phase 2 3Phase 3 3Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Managed Access Programs for ETB115, EltrombopagAvailableNCT04837703
- Eltrombopag Phase III Study In Chinese Chronic ITP PatientsCompletedNCT01762761Phase 3Results posted
- Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis CCompletedNCT00938860Phase 4Results posted
- Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral InfectionTerminatedNCT00582738Phase 2Results posted
- Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or TacrolimusTerminatedNCT00260208Phase 4Results posted
- Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected PatientsCompletedNCT01825980Phase 1/2
- Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE StudiesCompletedNCT01715779
- A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C PatientsTerminatedNCT01387958Phase 2
- MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C PositiveTerminatedNCT00284921Phase 3
- Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver TransplantationCompletedNCT00238901Phase 3